Study: NCT06294912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum
Description: Parasite inoculation administered by intravenous (IV) infusion as the challenge agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7602
Description: Capsules to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Description: Tablets to be administered orally as definitive antimalarial treatment.